Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Cwm LLC

Cwm LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4,033.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,705 shares of the biotechnology company’s stock after purchasing an additional 70,946 shares during the quarter. Cwm LLC owned about 0.07% of Sarepta Therapeutics worth $1,401,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. Federated Hermes Inc. raised its stake in Sarepta Therapeutics by 347.8% in the second quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company’s stock valued at $22,370,000 after buying an additional 1,016,069 shares during the last quarter. Norges Bank purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth about $15,619,000. Y Intercept Hong Kong Ltd increased its holdings in shares of Sarepta Therapeutics by 1,736.5% during the second quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company’s stock valued at $14,880,000 after acquiring an additional 822,799 shares in the last quarter. Aberdeen Group plc increased its holdings in shares of Sarepta Therapeutics by 91.1% during the second quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company’s stock valued at $21,500,000 after acquiring an additional 592,125 shares in the last quarter. Finally, 683 Capital Management LLC raised its position in shares of Sarepta Therapeutics by 309.1% in the 2nd quarter. 683 Capital Management LLC now owns 675,000 shares of the biotechnology company’s stock valued at $11,542,000 after purchasing an additional 510,000 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, COO Ian Michael Estepan sold 13,187 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the sale, the chief operating officer owned 193,300 shares in the company, valued at approximately $4,312,523. This trade represents a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.60% of the company’s stock.

Sarepta Therapeutics Stock Down 1.0%

Shares of SRPT stock opened at $21.31 on Monday. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $129.84. The stock has a market cap of $2.23 billion, a P/E ratio of -7.08, a P/E/G ratio of 0.46 and a beta of 0.48. The stock has a 50 day moving average of $20.61 and a 200 day moving average of $19.43. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The firm had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.Sarepta Therapeutics’s revenue for the quarter was down 14.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.62 EPS. As a group, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SRPT. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Barclays lowered their price objective on shares of Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 5th. Mizuho raised shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $19.00 to $26.00 in a report on Wednesday, November 5th. BMO Capital Markets raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Monday, September 22nd. Finally, Royal Bank Of Canada lifted their price target on Sarepta Therapeutics from $14.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $33.68.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.